Verrica Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Verrica Pharmaceuticals Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue7.575.129.0312.000.000.000.00
Cost of Revenue2.740.500.7315.930.000.000.00
Gross Profit4.835.128.31-3.930.000.000.00
Operating Expenses
Research & Development11.8420.3012.2015.9315.6715.4412.83
Selling, General & Administrative58.8247.3117.4126.9824.5114.649.05
Operating Expenses70.6670.8829.6026.9840.1830.0821.88
Operating Income-65.84-65.76-21.30-30.91-40.18-30.08-21.88
Other Income/Expense
Interest Income1.422.740.480.120.520.001.23
Interest Expense9.41-3.962.17-4.30-3.030.000.00
Other Income/Expense-2.752.55-1.500.000.000.000.00
Income
Income Before Tax-76.58-62.29-24.49-35.08-42.69-28.21-20.65
Income Tax Expense0.00-1.55-0.96-2.70-2.940.000.00
Net Income-76.58-67.00-24.49-35.08-42.69-28.21-20.65
Net Income - Continuous Operations-76.58-67.00-24.49-35.080.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-65.90-67.73-21.60-30.66-40.14-29.01-21.86
EBIT-67.17-68.54-22.32-30.91-40.18-28.21-21.88
Depreciation & Amortization1.270.500.720.240.04-0.060.00
Earnings Per Share
Basic EPS-15.00-1.00-7.00-13.00-17.00--1.00
Diluted EPS-15.00-1.00-7.00-13.00-17.00-1.00-1.00
Basic Shares Outstanding5.1845.343.422.702.5024.9014.66
Diluted Shares Outstanding5.1845.343.422.702.5024.9014.66